2024-11-15T01:30:40-06:00 2023-12-31 221478099 COHNREZNICK LLP 7501 WISCONSIN AVENUE SUITE 400E BETHESDA MD 20814 990 2023-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC AMER 5714831300 2318 MILL ROAD 800 ALEXANDRIA VA 22314 MELINDA O'LEARY CFO 5714831300 2024-11-14 1 1 LORI ROTHE YOKOBOSKY CPA P01273422 3016529100 2024-11-13 2023 2024-10-15 13:58:12Z ASCO CLIFFORD HUDIS MD CEO 2318 MILL ROAD 800 ALEXANDRIA VA 22314 202755721 0 X WWW.ASCO.ORG X 1965 NY SEE SCHEDULE O:ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY, EQUITABLE PATIENT CARE. 18 18 520 4125 13695298 6952857 9250760 16259283 123943513 127986242 2024051 23661513 10921536 6430255 146139860 174337293 4042358 4632496 0 0 64467166 70278616 0 0 0 75760362 80576931 144269886 155488043 1869974 18849250 251452025 296538439 107117119 112691951 144334906 183846488 X SEE SCHEDULE O: 0 0 64315059 440180 99649143 SEE SCHEDULE O:SCIENTIFIC & MEDICAL EDUCATION:ASCO'S MEETING PORTFOLIO DELIVERS TO ASCO'S CORE AUDIENCE OF HEALTH PROFESSIONALS, THE SCIENCE AND EDUCATION CRITICAL TO IMPROVING PATIENT CARE AND CLINICAL PRACTICE BY HOSTING CONFERENCES THAT BRING TOGETHER FACULTY AND PRACTITIONERS BOTH IN-PERSON AND ONLINE. IN 2023, ASCO'S PREMIER ANNUAL MEETING, THROUGH OVER 220 SESSIONS, REACHED AN AUDIENCE OF 36,750 PROFESSIONALS, INCLUDING OVER 14,000 PROFESSIONALS FROM 140 NON-US COUNTRIES, BOTH IN-PERSON AND ONLINE. THROUGH ASCO'S ADDITIONAL MEETINGS, THE ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, THE ASCO GENITOURINARY CANCERS SYMPOSIUM, THE ASCO QUALITY CARE SYMPOSIUM, ASCO BREAKTHROUGH, AND THE BEST OF ASCO ANNUAL MEETING, A FURTHER 11,325 PROFESSIONALS, OVER 4,600 OF WHOM WERE OUTSIDE THE UNITED STATES, BENEFITED FROM THE EDUCATION, SCIENCE, AND NETWORKING THAT ASCO PROVIDED. 22720123 5000 6060926 SEE SCHEDULE O:QUALITY OF CARE INITIATIVES - CANCERLINQ, QUALITY MEASURES, GUIDELINES AND QOPI:QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY SELF ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES: QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICES TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. PRACTICES PARTICIPATE ANNUALLY AND OVER 263 PRATICES PARTICAPTED IN 2023.QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO EDUCATE AND TRAIN HEMATOLGY-ONOCOLOGY PRACTICE TEAMS, THE TECHNIQUES OF CLINICAL CARE AND OPERATIONAL PERFORMANCE QUALITY IMPROVEMENT. RECENT PARTICPANTS HAVE INCLUDED, BY INTENTIONAL RECRUITMENT, PRACTICES SERVING URBAN AND RURAL UNDERSERVED POPULATIONS ADRESSING HEALTH DISPARITY. 290 ONCOLOGY PROFESSIONALS RECEIVED TRAINING IN 2023.GUIDELINES:A CRITICAL COMPONENT OF THE SOCIETY'S QUALITY EFFORTS, THE ASCO GUIDELINES PROGRAM ACTIVELY ENGAGES WITH MORE THAN 1,000 ASCO MEMBER VOLUNTEERS, ON A YEARLY BASIS, TO DEVELOP EVIDENCE AND EXPERT-DRIVEN RECOMMENDATIONS THAT INFORM HIGH-QUALITY AND EQUITABLE CANCER CARE WORLDWIDE. ASCO'S GUIDELINES PROGRAM WHICH INCLUDES TRADITIONAL AS WELL AS LIVING CLINICAL PRACTICE GUIDELINES, UPDATES, AND ORGANIZATIONAL STANDARDS, FOCUSES ON CONTENT AREAS WITH IDENTIFIED KNOWLEDGE GAPS, HIGH UNCERTAINTY, OR UNMET AND PRESSING CLINICAL NEEDS FACING ONCOLOGY CARE TEAMS IN CLINICAL PRACTICE. ASCO'S GUIDELINES RESOURCES ARE DESIGNED TO PROMOTE GUIDELINE-CONCORDANT CANCER CARE AT THE CLINICIAN, CAREGIVER, AND PATIENT LEVEL. FOR PATIENTS AND CAREGIVERS, COMPLEX GUIDELINE INFORMATION IS DISTILLED AND PRESENTED IN A USER-FRIENDLY FORMAT THROUGH ASCO'S CANCER.NET. FOR CLINICIANS, THESE TOOLS ARE OFFERED THROUGH CONCISE PRACTICE-FACING COMPANION ARTICLES, SUMMARY RECOMMENDATION TABLES, ALGORITHMS, PODCASTS, VISUAL ABSTRACTS, AND OTHER RESOURCES THAT ARE ACCESSIBLE THROUGH ASCO JOURNALS, THE ASCO WEBSITE, AND THE ASCO GUIDELINES APP.PUBLISHED AS A REGULAR, AND OFTEN MOST READ, FEATURE IN THE JOURNAL OF CLINICAL ONCOLOGY (JCO) WITH OVER 1.3 MILLION DOWNLOADS IN 2023, GUIDELINES ALSO SERVE AS THE EVIDENCE FOUNDATION FOR ASCO'S MEMBER EDUCATION, PATIENT EDUCATION, POLICY, CARE DELIVERY, AND QUALITY EFFORTS, ALL WITH THE GOAL OF CANCER TREATMENT AND CARE INFORMED BY THE HIGHEST QUALITY EVIDENCE AND EXPERT INTERPRETATION, INTEGRATED INTO GLOBAL PRACTICE AT THE POINT OF PATIENT CARE. ASCO TYPICALLY ENGAGES 30-40 GUIDELINE EXPERT PANELS AT ANY GIVEN TIME AND PUBLISHES BETWEEN 20-25 NEW OR UPDATED GUIDELINES EACH YEAR; WITH A GROWING LIBRARY OF GUIDELINE SUMMARIES THAT HAVE BEEN TRANSLATED INTO SPANISH. TWENTY-THREE GUIDELINE PRODUCTS WERE PUBLISHED IN THE JCO IN 2023, INCLUDING SEVERAL RAPID UPDATES AND MULTIPLE ITERATIONS OF ASCO'S COMPREHENSIVE LIVING GUIDELINE ADDRESSING THE CARE OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER. IN ADDITION, 13 COMPANION ARTICLES PROVIDING GUIDELINE CLINICAL INSIGHTS WERE PUBLISHED IN THE JCO ONCOLOGY PRACTICE. 9157287 4332922 SEE SCHEDULE O:RESEARCH INITIATIVES - TAPUR/CENTRA:ASCO'S CENTER FOR RESEARCH AND ANALYTICS LEADS ASCO'S RESEARCH EFFORTS, INCLUDING ITS CLINICAL CANCER RESEARCH PROGRAMS. MAJOR PROGRAMS AND PROJECTS INCLUDE: (1) THE TARGETED AGENT AND PROFILING UTILIZATION REGISTRY WHICH IS PRECISION MEDICINE BASKET TRIAL INVESTIGATING THE EFFICACY OF MORE THAN 15 DIFFERENT ANTI-CANCER TARGETED AGENTS IN PATIENTS WITH ADVANCED CANCERS AND HAS ENROLLED ALMOST THAN 3,000 PATIENTS SINCE IT OPENED IN 2016 AND CONTINUES TO PUBLISH TRIAL RESULTS IN PEER-REVIEWED CLINICAL CANCER RESEARCH JOURNALS AND PRESENT RESULTS AT CLINICAL CANCER RESEARCH CONFERENCES; (2) ASCO'S COVID-19 REGISTRY WHICH INCLUDES A DATABASE OF OVER 6,000 PATIENTS WITH CANCER AND COVID-19 FROM 2020 TO 2022 AND RESEARCH ON THE DATABASE BY CENTRA STAFF AND MADE AVAILABLE TO EXTERNAL RESEARCHERS (THE REGISTRY CLOSED TO DATA COLLECTION AT THE END OF 2023 ALTHOUGH DATA IS STILL AVAILABLE FOR USE); (3) ASCO'S MEMBER RESEARCH SURVEY POOL, WHICH FACILITATES RESEARCH OF CANCER CARE PROVIDERS BY DISSEMINATING SURVEYS FROM MERITORIOUS SURVEY RESEARCH PROJECTS TO ASCO MEMBERS WHO HAVE AGREED TO BE A PART OF THE SURVEY POOL; (4) THE STATE OF CANCER CARE IN AMERICA PROGRAM, WHICH ASSESSES AND REPORTS ON AND REPORT ON THE STATE OF AND CHANGES IN CANCER CARE IN THE US; (5) ASCO'S WORK IN IMPROVING ACCESS TO CLINICAL TRIALS THROUGH TRAINING FOR SITES AND WORKING TO COMBAT BARRIERS TO ENROLLMENT FOR UNDER-REPRESENTED POPULATIONS OF PATIENTS; AND (6) THE START-UP FOR A NEW CLINICAL RESEARCH STUDY, THE CDK4/6 INHIBITOR DOSING STUDY, WHICH WILL OPEN TO ENROLLMENT IN 2024 AND EVALUATES STANDARD VS. TITRATED DOSING APPROACHES FOR PATIENTS AGE 65 AND OLDER WITH HR+/HER2- METASTATIC BREAST CANCER. CENTRA ALSO SUPPORTS WORKSHOPS, MEETINGS, AND RESEARCH PROJECTS WITH OTHER STAKEHOLDERS IN CANCER RESEARCH, INCLUDING THE NCI, THE FDA'S ONCOLOGY CENTER FOR EXCELLENCE, AND OTHER NON-PROFIT GROUPS, SUCH AS THE FRIENDS OF CANCER RESEARCH. 28526865 4187316 17943251 EXAMPLES OF OTHER PROGRAMS:SCIENTIFIC PUBLICATIONS: ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS AND GENERAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. ASCO PUBLISHES HIGH-QUALITY, PEER-REVIEWED SCIENTIFIC PAPERS IN ITS JOURNALS: - JOURNAL OF CLINICAL ONCOLOGY (JCO)- JCO GLOBAL ONCOLOGY (JCO GO)- JCO CLINICAL CANCER INFORMATICS (JCO CCI)- JCO PRECISION ONCOLOGY (JCO PO)- JCO ONCOLOGY PRACTICE (JCO OP)- ASCO DAILY NEWSASCO ALSO PROVIDES CONTENT AND DISTRIBUTION LISTS FOR TRADE PUBLICATIONS. WHILE NOT OWNED OR PUBLISHED BY ASCO, THE PUBLICATIONS COVER NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY.CENTER FOR GLOBAL IMPACT:ASCO'S INTERNATIONAL AFFAIRS DEPARTMENT HAS TRANSITIONED TO THE CENTER FOR GLOBAL IMPACT (CGI). CGI PARTNERS ACROSS ASCO AND ONCOLOGY COMMUNITIES WORLDWIDE TO INTEGRATE GLOBAL PERSPECTIVES INTO ASCO STRATEGIES AND OPERATIONS, AND TO CATALYZE AND ADVANCE ASCO'S GLOBAL IMPACT GOALS AS DIRECTED BY THE SOCIETY'S MISSION, VISION, AND STRATEGIC PLANS. CGI SERVES AS A RESOURCE ACROSS ASCO FOR GLOBAL ISSUES RELEVANT TO ASCO, WITH A PARTICULAR EMPHASIS ON VOLUNTEER ENGAGEMENT, DIPLOMACY, STRATEGIC PLANNING, PROGRAM DELIVERY, AND GLOBAL OPERATIONS. IT DOES THIS THROUGH THE FOLLOWING:JOINT SESSIONS (INTERNATIONAL CANCER CONFERENCES)THE INTERNATIONAL CANCER CORPS' (ICC)THE INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA) 28526865 4187316 17943251 124719334 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 1 629 0 1 520 1 1 1 0 0 0 0 0 0 0 0 0 1 0 X 18 18 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 CA NY VA X MELINDA O'LEARY CFO 5714831300 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 EVERETT E VOKES MD CHAIR/PAST PRESIDENT 1.00 1.00 X X 0 0 0 ERIC P WINER MD PRESIDENT/CHAIR 1.00 1.00 X X 0 0 0 LYNN M SCHUCHTER MD PRESIDENT-ELECT/PRESIDENT 1.00 2.00 X X 0 0 0 ROBIN ZON MD PRESIDENT-ELECT 1.00 1.00 X X 0 0 0 LORI J PIERCE MD PAST PRESIDENT (PARTIAL YEAR) 1.00 1.00 X X 0 0 0 ELIZABETH A MITTENDORF MD PHD MHC TREASURER (PARTIAL YEAR) 1.00 1.00 X X 0 0 0 ELIZABETH R PLIMACK MD MS TREASURER-ELECT/TREASURER 1.00 1.00 X X 0 0 0 TAOFEEK K OWONIKOKO MD PHD TREASURER-ELECT 1.00 1.00 X X 0 0 0 FREDRICK CHITE ASIRWA MD MBCHB BOARD MEMBER 1.00 X 0 0 0 ETHAN M BASCH MD MSC BOARD MEMBER (PARTIAL YEAR) 1.00 1.00 X 0 0 0 LISA A CAREY MD BOARD MEMBER 1.00 1.00 X 0 0 0 MARIANA CHAVEZ MACGREGOR MD MSC BOARD MEMBER 1.00 X 0 0 0 TARA O HENDERSON MD MPH BOARD MEMBER 1.00 1.00 X 0 0 0 CAROLYN B HENDRICKS MD BOARD MEMBER 1.00 X 0 0 0 KATHLEEN N MOORE MD MS BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 ANN H PARTRIDGE MD MPH BOARD MEMBER 1.00 X 0 0 0 DEBRA PATT MD PHD BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 ENRIQUE SOTO PEREZ DE CELIS MD MSC BOARD MEMBER 1.00 1.00 X 0 0 0 GLADYS I RODRIGUEZ MD BOARD MEMBER 1.00 X 0 0 0 JENNIFER TEMEL MD BOARD MEMBER 1.00 X 0 0 0 MICHAEL A THOMPSON MD PHD BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 KAREN M WINKFIELD MD PHD BOARD MEMBER 1.00 X 0 0 0 CLIFFORD A HUDIS MD CEO 30.00 7.50 X 1060801 0 24750 DINA MICHELS ESQ SECRETARY, EVP & COO 37.50 X 685749 0 42792 LINDA JENSEN EVP & CFO 30.00 7.50 X 477532 0 42792 JULIE R GRALOW MD EVP & CMO 37.50 X 632400 0 42792 NANCY DALY MS MPH EVP & CONQUER CANCER CEO 1.00 36.50 X 516637 0 42677 CARMEN JACKSON CEO - CLQ 37.50 X 515125 0 49419 CHRISTOPHER MERLAN EVP & CHIEF DIGITAL OFFICE 37.50 X 475728 0 44731 JAMIE VON ROENN MD MED VP, EDU., SCIENCE & PROF. 37.50 X 457512 0 33834 AMANDA DAVIS-AITKEN VICE PRESIDENT, MEETING SV 37.50 X 338635 0 33749 ANGELA COCHRAN VP, PUBLISHING 37.50 X 336979 0 40401 BARTON LAWYER VICE PRESIDENT - IT 37.50 X 303038 0 47169 STEPHEN GRUBBS MD VP, CARE DELIVERY 37.50 X 445051 0 42606 KRISTEN NEESE CHIEF MARKETING & COMMUNICATIONS OFFICER 37.50 X 363368 0 44731 PAULA KING CHIEF HUMAN RESOURCES OFFICER 37.50 X 362762 0 44731 DEBORAH KAMIN PHD VP, POLICY/ADVOCACY 30.00 7.50 X 356959 0 42677 MELISSA TAI VP, CEIL & GENERAL COUNSEL 29.50 8.00 X 350115 0 49281 SEAN KHOZIN MD FORMER CLQ CEO 37.50 X 395769 0 0 8074160 0 669132 237 1 1 0 FREEMAN PO BOX 734596 DALLAS TX 753734596 EVENT MANAGEMENT 9904419 THOUGHTWORKS INC 3799 PAYSPHERE CIRCLE CHICAGO IL 60674 IT CONSULTING 7093917 SPARGO INC 11208 WAPLES MILL ROAD 112 FAIRFAX VA 22030 EVENT MANAGEMENT 4797390 SMG FOOD & BEVERAGE LLC 747 HOWARD ST SAN FRANCISCO CA 94103 CATERING 4376569 AMAZON WEB SERVICES PO BOX 84023 SEATTLE WA 981248423 IT SERVICES 3573335 92 7804140 8365143 90000 16259283 EDUCATIONAL MTGS & FEE 900099 98287118 90465620 7821498 SCIENTIFIC PUBLICATION 513120 16950485 11119034 5831451 RESEARCH 900099 6130989 6130989 QUALITY OF CARE 900099 5871793 5871793 OTHER 900099 745857 703508 42349 127986242 5782594 5782594 5450417 5450417 979838 0 979838 979838 979838 21297347 25000000 22935037 5483391 -1637690 19516609 17878919 17878919 174337293 114290944 13695298 30091768 X 4616736 4616736 15760 15760 6641015 5199633 1441382 49159160 38489539 10669621 3672281 2875240 797041 6598315 5166201 1432114 4207845 3294564 913281 721399 681188 40211 136900 2500 134400 104026 104026 24842957 18916090 5926867 705816 693882 11934 5420746 3834822 1585924 9692065 6893709 2798356 3198932 1925134 1273798 5802064 4824036 978028 20612159 20607946 4213 1073425 614692 458733 3852923 2206359 1646564 861769 624700 237069 UBI TAX- FEDERAL AND ST 1896781 1896781 CLINICAL SITE PAYMENTS 1336000 1336000 BAD DEBT 315147 315147 OTHER 3822 3822 155488043 124719334 30768709 0 15476157 9395785 11423325 12675262 5887690 8339401 90209121 37019482 47258609 53189639 166910803 208311312 4495441 4627040 251452025 296538439 9387248 11247077 46146231 52717228 46440487 43521229 5143153 5206417 107117119 112691951 X 143605840 183557748 729066 288740 144334906 183846488 251452025 296538439 18849250 20662332 0 X 0 1 X 1 1 1 X 7525300 6446971 7826511 9250760 16259283 47308825 123116955 98737324 80888354 108839499 114290944 525873076 130642255 105184295 88714865 118090259 130550227 573181901 75000 75000 0 75000 75000 573106901 8610595 18248056 15214892 15080053 12212849 69366445 8610595 18248056 15214892 15080053 12212849 69366445 7776132 8302393 7677032 8115539 6952857 38823953 251085 251085 147280067 131734744 111606789 141285851 149715933 681623384 0.84080 0.85180 0.10180 0.09410 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 155488043 155488043 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 250000 250000 250000 250000 1000000 1500000 54234015 18104403 36129612 763557 760108 3449 13153695 8284385 4869310 22057854 9870586 12187268 53189639 DEFERRED COMPENSATION LIABILITY 3205311 OPERATING LEASE OBLIGATION 2001106 5206417 X PART X, LINE 2: THE ORGANIZATION ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH THE INCOME TAX TOPIC OF THE FINANCIAL ACCOUNTING STANDARDS BOARD ACCOUNTING STANDARDS CODIFICATION ("FASB ASC"). THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN AND, AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. GENERALLY, THE ORGANIZATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE 2020. 1 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 5 PROGRAM SERVICES QUALITY OF CARE 1062285 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 75268 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 78366 SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 71366 SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 17690 SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 44233 RUSSIA AND NEIGHBORING STATES - ARMENIA, AZERBIJAN, BELARUS, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 41378 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 3132 0 5 0 0 0 5 1393718 0 1393718 EUROPE (INCLUDING ICELAND & GREENLAND) WORLD CANCER LEADER'S SUMMIT 15760 0 1 0 0 0 0 0 1 PART I, LINE 2: ASCO PROVIDED HONORARIA AND EXPENSE REIMBURSEMENTS TO MEETING SPEAKERS AND PRESENTERS. HONORARIA AND EXPENSE REIMBURSEMENTS WERE PAID DIRECTLY TO THE PRESENTERS. PART I, LINE 3: THE ACCRUAL METHOD WAS USED TO ACCOUNT FOR EXPENDITURES IN RELATION TO FOREIGN PROGRAM SERVICES. 1 NATIONAL ACADEMY OF SCIENCES 500 FIFTH STREET NW 8TH FLOOR WASHINGTON DC 20001 530196932 501(C)(3) 20000 0 SPONSORSHIP - ROUNDTABLE ON GENOMICS AND PRECISION HEALTH NATIONAL COALITION FOR CANCER SURVIVORSHIP 8455 COLESVILLE RD SUITE 930 SILVER SPRINGS MD 20910 850357897 501(C)(3) 10000 0 CONTRIBUTION HEALTH VOLUNTEERS OVERSEAS 1900 L STREET NW STE 310 WASHINGTON DC 20036 521485477 501(C)(3) 10000 0 VOLUNTEER ONCOLOGY SITES UNIVERSITY OF CHICAGO 5801 ELLIS AVE CHICAGO IL 60637 362177139 501(C)(3) 74167 0 CONTRIBUTION BOARD OF REGENTS OF THE UNIVERSITY OF THE UNIVERSITY OF MICHIGAN 3003 S STATE ST SUITE 8000 ANN ARBOR MI 48109 386006309 501(C)(3) 12500 0 CONTRIBUTION YALE UNIVERSITY PO BOX 208239 NEW HAVEN CT 06520 060646973 501(C)(3) 130000 0 CONTRIBUTION BRIGHAM & WOMEN'S HOSPITAL INC 75 FRANCIS ST BOSTON MA 02116 042312909 501(C)(3) 25000 0 CONTRIBUTION UNIVERSITY OF PENNSYLVANIA 3451 WALNUT ST RM 305 PHILADELPHIA PA 19104 231352685 501(C)(3) 109167 0 CANCER RESEARCH & EDUCATION FOX CHASE CANCER CENTER 3509 N BROAD ST RM 936 PHILADELPHIA PA 19140 231352156 501(C)(3) 47500 0 CONTRIBUTION CONQUER CANCER FOUNDATION OF ASCO 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 311667995 501(C)(3) 3652500 0 CONTRIBUTION UNIVERISTY OF CINCINNATI 51 GOODMAN DRIVE CINCINNATI OH 45219 316000989 GOVT ENTITY 46667 0 CONTRIBUTION MAYO CLINIC JACKSONVILLE PO BOX 860334 MINNEAPOLIS MN 554860334 593337028 501(C)(3) 82400 0 CONTRIBUTION JOHN HOPKINS UNIVERSITY 3910 KESWICK ROAD SUITE N2100 BALTIMORE MD 21211 520595110 501(C)(3) 82400 0 CONTRIBUTION UNIVERSITY OF PITTSBURG 116 ATWOOD ST SUITE 201 PITTSBURGH PA 15213 250965591 501(C)(3) 15000 0 CONTRIBUTION UNIVERSITY OF FLORIDA PO BOX 14425 GAINSEVILLE FL 32604 590974739 501(C)(3) 82400 0 CONTRIBUTION UNIVERSITY OF TEXAS 2200 SAN ANTONIO ST AUSTIN TX 78705 270426799 501(C)(3) 82400 0 CONTRIBUTION MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE NEW YORK NY 10065 131924236 501(C)(3) 82400 0 CONTRIBUTION 17 0 PART I, LINE 2: ASCO PROVIDES ASSISTANCE TO ORGANIZATIONS THAT SERVE THE CANCER CARE COMMUNITY. THE MAJORITY OF THESE GRANTS ARE MADE TO OTHER 501(C)(3) ORGANIZATIONS. GRANTS MADE TO NON-501(C)(3) ORGANIZATIONS ARE MADE PURSUANT TO A WRITTEN AGREEMENT THAT REQUIRED THE GRANT FUNDS TO BE USED FOR SPECIFIC EDUCATIONAL AND CHARITABLE PROJECTS, THAT THE GRANTEE RETURN ANY PORTION OF THE GRANT FUNDS THAT WERE NOT USED FOR SUCH PROJECTS, AND THAT THE GRANTEE PROVIDE ANNUAL NARRATIVE AND FINANCIAL REPORTS TO ASCO REGARDING GRANTEE'S USE OF THE GRANT FUNDS. X X X X X 1 0 0 0 0 0 0 1 0 CLIFFORD A HUDIS MD CEO 1049613 0 10000 0 1188 0 24750 0 0 0 1085551 0 0 0 DINA MICHELS ESQ SECRETARY, EVP & COO 644561 0 40000 0 1188 0 24750 0 18042 0 728541 0 0 0 JULIE R GRALOW MD EVP & CMO 621212 0 10000 0 1188 0 24750 0 18042 0 675192 0 0 0 CARMEN JACKSON CEO - CLQ 499855 0 15000 0 270 0 24750 0 24669 0 564544 0 0 0 NANCY DALY MS MPH EVP & CONQUER CANCER CEO 504351 0 10000 0 2286 0 24750 0 17927 0 559314 0 0 0 CHRISTOPHER MERLAN EVP & CHIEF DIGITAL OFFICE 464954 0 10000 0 774 0 24750 0 19981 0 520459 0 0 0 LINDA JENSEN EVP & CFO 463824 0 10000 0 3708 0 24750 0 18042 0 520324 0 0 0 JAMIE VON ROENN MD MED VP, EDU., SCIENCE & PROF. 443804 0 10000 0 3708 0 24750 0 9084 0 491346 0 0 0 STEPHEN GRUBBS MD VP, CARE DELIVERY 431343 0 10000 0 3708 0 24750 0 17856 0 487657 0 0 0 KRISTEN NEESE CHIEF MARKETING & COMMUNICATIONS OFF 360954 0 2000 0 414 0 24750 0 19981 0 408099 0 0 0 PAULA KING CHIEF HUMAN RESOURCES OFFICER 351574 0 10000 0 1188 0 24750 0 19981 0 407493 0 0 0 DEBORAH KAMIN PHD VP, POLICY/ADVOCACY 343251 0 10000 0 3708 0 24750 0 17927 0 399636 0 0 0 MELISSA TAI VP, CEIL & GENERAL COUNSEL 339395 0 10450 0 270 0 24750 0 24531 0 399396 0 0 0 SEAN KHOZIN MD FORMER CLQ CEO 395769 0 0 0 0 0 0 0 0 0 395769 0 0 0 ANGELA COCHRAN VP, PUBLISHING 326709 0 10000 0 270 0 24750 0 15651 0 377380 0 0 0 AMANDA DAVIS-AITKEN VICE PRESIDENT, MEETING SV 328455 0 10000 0 180 0 24750 0 8999 0 372384 0 0 0 BARTON LAWYER VICE PRESIDENT - IT 292624 0 10000 0 414 0 22500 0 24669 0 350207 0 0 0 PART I, LINE 4A SEAN KHOZIN RECEIVED SEVERANCE IN THE AMOUNT OF $395,769 IN 2023. PART I, LINE 7 THE ORGANIZATION HAS A DISCRETIONARY BONUS PLAN UNDER WHICH SELECTED EMPLOYEES, INCLUDING OFFICERS, KEY EMPLOYEES, AND OTHER EMPLOYEES ARE COMPENSATED BASED ON PERFORMANCE AND THE ACHIEVEMENT OF ORGANIZATIONAL GOALS. BONUSES FOR KEY EMPLOYEES AND HIGHEST COMPENSATED EMPLOYEES ARE APPROVED BY THE CHIEF EXECUTIVE OFFICER WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. BONUSES FOR THE CHIEF EXECUTIVE OFFICER, IF ANY, ARE REVIEWED BY THE COMPENSATION COMMITTEE AS PART OF THE CHIEF EXECUTIVE OFFICER'S ANNUAL COMPENSATION REVIEW PROCESS, AND APPROVED BY THE BOARD OF DIRECTORS. IN ADDITION, THE ORGANIZATION AWARDS MODEST AMOUNTS TO EMPLOYEES ON ACHIEVING CERTAIN NUMBER OF YEARS OF EMPLOYMENT. FROM TIME TO TIME, THE ORGANIZATION MAY MAKE STANDARD PAYMENTS TO ITS EMPLOYEES IN GOOD STANDING WITH MINIMUM TIME OF EMPLOYMENT TO RECOGNIZE EFFORT AND COMMITMENT TO THE ORGANIZATION'S GOALS IN THAT YEAR. FORM 990, PART VI, SECTION A, LINE 1A AS OF DECEMBER 31, 2023, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDED TWO EX-OFFICIO DIRECTORS WITHOUT THE RIGHT TO VOTE, WHO WERE THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO) AND THE CHAIR OF THE BOARD OF DIRECTORS OF ASCO'S RELATED 501(C)(3) ORGANIZATION, THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. PURSUANT TO THE BYLAWS, THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE ARE THE PRESIDENT, THE PRESIDENT-ELECT, THE CHAIR, THE PAST PRESIDENT, THE TREASURER, THE TREASURER-ELECT, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR PRESENT TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS, AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED MEETING OF THE BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 6 ALL ASCO MEMBERS MUST BE ONCOLOGY MEDICAL PROFESSIONALS, DEFINED AS INDIVIDUALS WHO MEET ANY OF THE FOLLOWING QUALIFICATIONS: (1) INDIVIDUALS WHOSE PROFESSIONAL CREDENTIALS AND ACTIVITIES INVOLVE CANCER PATIENT CARE AND/OR RESEARCH, EDUCATION, OR ADVOCACY IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER; (2) INDIVIDUALS WHO ARE RETIRED FROM PROFESSIONAL ACTIVITIES, BUT WHOSE PROFESSIONAL ACTIVITIES PRIOR TO RETIREMENT INCLUDED THOSE SET FORTH ABOVE; (3) INDIVIDUALS WHO ARE STUDENTS TRAINING TO BE PROFESSIONALS DESCRIBED ABOVE. VOTING MEMBERS ARE ONCOLOGY MEDICAL PROFESSIONALS WHO HAVE BEEN AWARDED AND HOLD THE DEGREE OF DOCTOR OF MEDICINE, DOCTOR OF OSTEOPATHY, DOCTOR OF PHILOSOPHY, DOCTOR OF PHARMACY, DOCTOR OF MEDICAL SCIENCE, DOCTOR OF NURSING SCIENCE, DOCTOR OF NURSING PRACTICE, OR EQUIVALENT DOCTORAL-LEVEL DEGREE AS DETERMINED FROM TIME TO TIME BY ASCO AND THE ASSOCIATION. ONLY VOTING MEMBERS ARE ELIGIBLE TO VOTE OR SERVE ON THE BOARD OF DIRECTORS, ON THE NOMINATING COMMITTEE, OR AS ELECTED OFFICERS. FORM 990, PART VI, SECTION A, LINE 7A VOTING MEMBERS OF ASCO ELECT ALL VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7B ASCO'S CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED, AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. FORM 990, PART VI, SECTION B, LINE 11B AN ELECTRONIC COPY OF THE FINAL FORM WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS, AND WAS REVIEWED BY THE VICE PRESIDENT & CHIEF FINANCIAL OFFICER; THE CHIEF EXECUTIVE OFFICER; AND THE EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER & CHIEF LEGAL OFFICER PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICTS OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND CERTAIN FAMILY MEMBERS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER AND WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION-MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE EXECUTIVE VICE CHAIR OF ASCO'S NON-PROFIT, 501(C)(3) TAX- EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CC); THE CEO OF ASCO'S NON-PROFIT, 501(C)(6) TAX-EXEMPT RELATED ORGANIZATION, ASCO ASSOCIATION (D/B/A ASSOCIATION FOR CLINICAL ONCOLOGY)(ASSOCIATION), THE PRESIDENT OF QOPI CERTIFICATION PROGRAM, LLC; THE PRESIDENT OF ASCO LEASING LLC, AND THE CHAIR OF THE BOARD OF GOVERNORS OF CANCERLINQ LLC. ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2023. THE COMPENSATION OF THE FOLLOWING POSITIONS WAS CONSIDERED AND APPROVED BY THE ASCO BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND AN INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR EACH OF THE POSITIONS WAS REASONABLE. - EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER & CHIEF LEGAL OFFICER & ASCO SECRETARY (EVP & COO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & COO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2023. THE EVP & COO'S COMPENSATION WAS ALSO REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, AS REQUIRED UNDER STATE LAW. - EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (EVP & CFO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CFO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2023. - EXECUTIVE VICE PRESIDENT & CHIEF MEDICAL OFFICER (EVP & CMO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CMO BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2023. - EXECUTIVE VICE PRESIDENT & CHIEF DIGITAL OFFICER (EVP & CDO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CDO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2023. - EXECUTIVE VICE PRESIDENT OF ASCO & CHIEF EXECUTIVE OFFICER OF THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (EVP & CC CEO): THE EVP & CC CEO IS AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CC CEO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2023. - EXECUTIVE VICE PRESIDENT OF ASCO & CHIEF EXECUTIVE OFFICER OF CANCERLINQ LLC (EVP & CLQ CEO): THE EVP & CLQ CEO IS AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CC CEO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2023. FORM 990, PART VI, SECTION C, LINE 18 ASCO'S FORM 1023, 990 AND 990-T ARE MADE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 18,916,090. MANAGEMENT AND GENERAL EXPENSES 5,926,867. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 24,842,957. ASCO LEASING LLC 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 273378225 RENTAL VA 0 0 ASCO CANCERLINQ LLC 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 472315885 QUALITY IMPV VA 7558629 0 ASCO CONQUER CANCER FOUNDATION OF ASCO 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 311667995 GRANTMAKING VA 501(C)(3) LINE 7 ASCO 1 ASCO ASSOCIATION 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 833561693 MEMBER SERVS VA 501(C)(6) ASCO 1 ASCO ASSOCIATION POLITICAL ACTION COMM 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 844213157 ADVOCACY VA 527 ASCO ASSOC 0 CANCERLINQ LABS LLC 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 881804716 DATABASE TECHNOLOGY VA N/A C 0 0 1 1 0 0 0 0 0 0 1 0 1 1 1 1 1 1 0 0 CONQUER CANCER FOUNDATION OF ASCO B 3652500 FMV CONQUER CANCER FOUNDATION OF ASCO C 7804140 FMV ASCO ASSOCIATION N 821288 FMV CONQUER CANCER FOUNDATION OF ASCO N 158550 FMV ASCO ASSOCIATION Q 856123 FMV CONQUER CANCER FOUNDATION OF ASCO Q 8910923 FMV